摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-Propin-(2)-ylmercapto-isobuttersaeure | 89898-14-6

中文名称
——
中文别名
——
英文名称
α-Propin-(2)-ylmercapto-isobuttersaeure
英文别名
2-methyl-2-(2-propynylthio)propanoic acid;2-Methyl-2-(2-propynylthio)propionic acid;α-prop-2-ynylmercapto-isobutyric acid;α-Prop-2-inylmercapto-isobuttersaeure;2-Methyl-2-prop-2-inylmercapto-propionsaeure;2-Methyl-2-prop-2-ynylsulfanylpropanoic acid
α-Propin-(2)-ylmercapto-isobuttersaeure化学式
CAS
89898-14-6
化学式
C7H10O2S
mdl
——
分子量
158.221
InChiKey
JHSGSNJXGATUDN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    37-38 °C
  • 沸点:
    98-103 °C(Press: 0.2 Torr)
  • 密度:
    1.159±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    62.6
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Diagnostic radiopharmaceutical compounds (That)
    申请人:Amersham International plc
    公开号:US05690904A1
    公开(公告)日:1997-11-25
    Tetradentate ligands are used to form neutral 99m-technetium complexes which may be useful as radiopharmaceuticals e.g. as brain imaging agents. The ligands have the structure ##STR1## where n is 2 or 3, m is 0-4, R is H or substituted or unsubstituted C.sub.1 -C.sub.6 alkyl, provided that one CR.sub.2 group adjacent the starred nitrogen atom represents CO and forms with the adjacent N atom, a --CONH-- amide group, Y is unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, and one of X and X' represents H or a labile thiol protecting group while the other is unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, alkenyl or alkynyl.
    四齿配体被用来形成中性的99m锝配合物,这些配合物可能用作放射性药物,例如用作脑成像剂。这些配体具有结构##STR1##其中n为2或3,m为0-4,R为H或取代或未取代的C.sub.1 -C.sub.6烷基,条件是与星号氮原子相邻的一个CR.sub.2基团代表CO,并与相邻的N原子形成一个--CONH--酰胺基团,Y为未取代或取代的C.sub.1 -C.sub.6烷基,X和X'中的一个代表H或一种不稳定的硫醇保护基,而另一个是未取代或取代的C.sub.1 -C.sub.6烷基、烯基或炔基。
  • Indole Compounds, Method of Preparing Them and Uses Thereof
    申请人:BINET Jean
    公开号:US20080153816A1
    公开(公告)日:2008-06-26
    Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.
    与公式(I)相对应的吲哚化合物,如权利要求中所定义的,这些化合物的药学上可接受的加盐物,含有这些化合物的药物组合物,其制备方法,以及它们作为药理活性物质的用途,特别是在治疗高三酰甘油血症、高脂血症、高胆固醇血症、糖尿病、内皮功能障碍、心血管疾病、炎症性疾病和神经退行性疾病方面。
  • Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds
    申请人:BINET Jean
    公开号:US20100286137A1
    公开(公告)日:2010-11-11
    Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.
    本发明涉及化合物的吲哚类似物(I)的配方,这些化合物的药学上可接受的加盐物,含有这些化合物的制药组合物,其制备过程,以及作为药理活性物质的用途,特别是在高甘油三酯血症,高脂血症,高胆固醇血症,糖尿病,内皮功能障碍,心血管疾病,炎症性疾病和神经退行性疾病的治疗中。
  • US2874190
    申请人:——
    公开号:——
    公开(公告)日:——
  • US5026913A
    申请人:——
    公开号:US5026913A
    公开(公告)日:1991-06-25
查看更多